论文部分内容阅读
3′,4′-双脱氧卡那霉素B(Dibekacin,DBK)是由卡那霉素B衍生而得的半合成氨基糖苷类抗生素,早在1971年日本已进行了DBK的研究,1973年后用于临床治疗各种感染疾病。本研究的目的是检查DBK的体外活性,并同艮他霉素作比较。用琼脂稀释法对临床分离的221株试验菌测定了最小抑菌浓度(M IC)值。其中195株为艮他霉素敏感菌株(MIC≤8微克/毫升),包括金黄色葡萄球菌、克氏杆菌、大肠杆菌、奇异变形杆菌、吲哚阳性变形杆菌、赛氏杆菌、肠道杆菌、绿脓杆菌;26株为艮他霉素耐药菌株(MIC>8微克/毫升),包括绿脓杆菌、黏质赛氏杆菌、金黄色葡萄球菌、大肠杆菌。比较结果:对艮
3 ’, 4’-dideoxykanamycin B (DBK) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin B. As early as 1971, DBK has been studied in Japan. After the clinical treatment of various infectious diseases. The purpose of this study was to examine the in vitro activity of DBK and to compare it with gentamicin. The minimum inhibitory concentration (M IC) value of 221 clinical isolates was determined by agar dilution method. Among them, 195 strains were gentamicin-sensitive strains (MIC≤8 μg / ml) including Staphylococcus aureus, Klebsiella, Escherichia coli, Proteus mirabilis, Proteus indole, Proteus, Enterobacter, Pseudomonas aeruginosa; 26 strains of gentamicin-resistant strains (MIC> 8 μg / ml), including Pseudomonas aeruginosa, Leishmania bacteria, Staphylococcus aureus, Escherichia coli. Compare the results: Gen